Eli Lilly To Present Fresh Data On Foundayo, Retatrutide In Europe — Here’s Why Berenberg Sees A 21% Potential Upside In LLY Stock
Eli Lilly (LLY) was in the spotlight on Tuesday after Berenberg upgraded the pharmaceutical giant, citing potential upside to its 2026 outlook, as the company prepares to unveil new data later this month for several next-generation obesity and diabetes treatments.LLY shares were up 1.3% at the time…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.